OS Therapies (OSTX) Net Income (2023 - 2026)
OS Therapies' (OSTX) quarterly Net Income came in at -$10.3 million in Q1 2026, down 106.45% YoY from $159.9 million in Q1 2025, and up 23.32% on a QoQ basis from -$13.5 million in Q4 2025.
OS Therapies (OSTX) Net Income (2023 - 2026) Analysis & Trends
OS Therapies (OSTX) has 4 years of Net Income data on file, last reported at -$10.3 million in Q1 2026.
- Quarterly Net Income fell 106.45% year-over-year to -$10.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$36.4 million (down 193.76% YoY) and the FY2025 annual result came in at -$30.2 million, down 97.05% from the prior year.
- Net Income rose to -$10.3 million in Q1 2026, from -$13.5 million in the prior quarter.
- In the past five years, Net Income ranged from a high of -$1.5 million in Q4 2023 to a low of -$13.5 million in Q4 2025.
- A 4-year average of -$4.5 million and a median of -$2.9 million in 2024 frame the typical range for Net Income.
- Annual changes were most pronounced in 2024 — Net Income soared 37.83% — and 2025, when it sank 352.62%.
- Tracing OSTX's Net Income over 4 years: stood at -$1.5 million in 2023, then slumped by 103.06% to -$3.0 million in 2024, then slumped by 352.62% to -$13.5 million in 2025, then grew by 23.32% to -$10.3 million in 2026.
- The last three Net Income figures came in at -$10.3 million (Q1 2026), -$13.5 million (Q4 2025), and -$7.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.40 Bn | 131.55 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 86.53 Bn | 78.54 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 65.20 Bn | 60.02 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 60.40 Bn | 55.26 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 42.17 Bn | 37.07 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.36 Bn | 28.05 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.74 Bn | 10.34 Bn | 668.28 Mn | -355.03 Mn |
| 8 | Insmed | 27.45 Bn | 26.29 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.17 Bn | 26.33 Bn | - | 81.49 Mn |
| 10 | OS Therapies | 20.06 Mn | 20.06 Mn | - | -8.63 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -10.32 Mn |
| Dec 31, 2025 | -13.46 Mn |
| Sep 30, 2025 | -7.38 Mn |
| Jun 30, 2025 | -5.29 Mn |
| Mar 31, 2025 | -5.00 Mn |
| Dec 31, 2024 | -2.97 Mn |
| Sep 30, 2024 | -2.88 Mn |
| Jun 30, 2024 | -1.56 Mn |
| Mar 31, 2024 | -1.72 Mn |
| Dec 31, 2023 | -1.46 Mn |
| Sep 30, 2023 | -1.97 Mn |
| Jun 30, 2023 | -2.51 Mn |
| Mar 31, 2023 | -1.85 Mn |